Shorepoint Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Shorepoint Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$4.07M	Buy	+10,405	New	+$4.35M	0.81%	50
2025 Q1	$4.89M	Buy	10,090 +280	+3%	+$130K	1.11%	32
2024 Q4	$3.95M	Buy	9,810 +280	+3%	+$130K	0.9%	40
2024 Q3	$4.43M	Sell	9,530 -44	-0.5%	-$21.1K	1.01%	38
2024 Q2	$4.49M	Buy	9,574 +606	+7%	+$263K	1.05%	36
2024 Q1	$3.75M	Sell	8,968 -162	-2%	-$68.5K	0.92%	43
2023 Q4	$3.71M	Buy	9,130 +130	+1%	+$48K	1%	41
2023 Q3	$3.13M	Buy	9,000 +466	+5%	+$163K	0.92%	42
2023 Q2	$3M	Buy	8,534 +511	+6%	+$172K	0.85%	42
2023 Q1	$2.53M	Buy	8,023 +773	+11%	+$232K	0.72%	52
2022 Q4	$2.09M	Buy	+7,250	New	+$2.21M	0.58%	58

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Shorepoint Capital Partners's VRTX Position: Q3 2025 in Review

Shorepoint Capital Partners opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2025: 10,405 shares worth $4.07M. The stake represents 0.81% of the portfolio and ranks #50 among its holdings. This is a return to the name: Shorepoint Capital Partners previously reported a position in VRTX as recently as Q1 2025.

Shorepoint Capital Partners first reported a position in VRTX in Q4 2022 and has held it in 11 quarters since. The position peaked at $4.89M in Q1 2025. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

Shorepoint Capital Partners held 10,405 shares of Vertex Pharmaceuticals worth $4.07M as of Q3 2025.
Vertex Pharmaceuticals was a new Shorepoint Capital Partners position in Q3 2025.
Vertex Pharmaceuticals made up 0.81% of Shorepoint Capital Partners's portfolio in Q3 2025, its #50 holding.
Shorepoint Capital Partners first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
Shorepoint Capital Partners's Vertex Pharmaceuticals position peaked at $4.89M in Q1 2025.
1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Shorepoint Capital Partners's 13F filing for Q3 2025, filed 3 Oct 2025.